STOCK TITAN

NEMAURA MEDICAL INC - $NMRD STOCK NEWS

Welcome to our dedicated page for NEMAURA MEDICAL news (Ticker: $NMRD), a resource for investors and traders seeking the latest updates and insights on NEMAURA MEDICAL stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NEMAURA MEDICAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NEMAURA MEDICAL's position in the market.

Rhea-AI Summary
Nemaura Medical completes 100-patient study for sugarBEAT® sensor, interim results show potential for 24-hour wear period and improved user experience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
none
-
Rhea-AI Summary
Nemaura Medical receives SFDA approval for sugarBEAT glucose sensor in Saudi Arabia, a major breakthrough in product commercialization in the Middle East
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.77%
Tags
-
Rhea-AI Summary
Nemaura Medical released Q2 2023 financial results, with R&D expenses of $549,012 and general and administrative expenses of $1,508,467. Cash and cash equivalents at the end of June 2023 were $4m, and the company secured an additional $6.5m in clean debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
Rhea-AI Summary
Nemaura Medical, Inc. has secured $6.5 million in non-dilutive funding through a clean debt facility. The company received positive feedback at the American Diabetes Association meeting and is conducting studies with the NHS. It is also supporting its UK licensee with the reimbursement application for sugarBEAT® in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.93%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
none
NEMAURA MEDICAL INC

Nasdaq:NMRD

NMRD Rankings

NMRD Stock Data

2.46M
14.84M
48.62%
4.41%
0.18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
New York

About NMRD

nemaura medical inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. the company provides sugarbeat, a non-invasive continuous glucose monitoring device for use by persons with type i and type ii diabetes, as well as for screening pre-diabetic patients. it has a license agreement with healthimation, llc, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for type 2 diabetes, prediabetes, and general wellness; the why wait app; and common law trademarks which incorporate the mark why wait or whywait and the use of licensed marks. nemaura medical inc. was founded in 2009 and is based in new york, new york.